

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jacques F. BANCHEREAU et al.

Mail Stop: PCT

U.S. Application No.: 10/042,644

Filing or 371(c) Date: January 08, 2002

Group Art Unit: 1646

Title: Methods for Treating Autoimmune Diseases
in a Subject and In Vitro Diagnostic Assays

Examiner: Gyan Chandra

Confirmation No.: 7691

TENTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. A copy of each of the documents cited and required by 37 C.F.R. § 1.98 is enclosed.

This Information Disclosure Statement is being submitted after the period specified in 37 C.F.R. § 1.97(c). In accordance with 37 C.F.R. § 1.97(d)(1), the statement specified in 37 C.F.R. § 1.97(e) is provided below. In accordance with 37 C.F.R. § 1.97(d)(2), please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p). Consideration of the information provided herein is respectfully requested.

Each item of information contained in the Information Disclosure Statement was first cited in a communication from the Japanese Patent Office in corresponding Japanese Patent Application No. 2002-567137 not more than three months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO/SB/08. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees that may be required by this paper, and to credit any overpayment, to Deposit Account No. 50-3218.


Respectfully submitted,

HUTCHISON LAW GROUP PLLC

Date:

May 22, 2008

By



Joshua T. Elliott

Registration No. 43,603

P.O. Box 31686
Raleigh, NC 27612
+1.919.829.9600